Physician profile
Hetal Sheth
NPI 1265742175
$1,227.16
in general payments reported to CMS, 2019-2025
11 companies · $97.75 in 2025
The $97.75 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $200 · 2022: $213 · 2023: $449 · 2024: $267 · 2025: $97.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $292.53 | 2023-2025 | Fetroja |
| Takeda Pharmaceuticals U.S.A., INC. | $205.95 | 2022-2025 | Gattex |
| Chiesi USA, INC. | $203.46 | 2021-2025 | Cleviprex |
| Janssen Pharmaceuticals, INC | $118.50 | 2021-2023 | Xarelto |
| Melinta Therapeutics, LLC | $111.11 | 2022-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Alcresta Therapeutics, INC. | $92.30 | 2023 | Relizorb |
| Kci USA, INC. | $85.51 | 2021-2023 | Prevena Restor Bellaform, V.A.C. Veraflo Cleanse Choice, V.A.C. Dermatac |
| La Jolla Pharmaceutical Company | $39.04 | 2023 | Giapreza |
| Merck Sharp & Dohme LLC | $32.93 | 2024 | |
| W. L. Gore & Associates, INC. | $30.39 | 2021 | |
| Biocomposites INC | $15.44 | 2025 | Stimulan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hetal Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.